1. FINESSE: Study Design
Acute ST Elevation MI (or New LBBB) within 6h pain onset
Presenting at Hub or Spoke with estimated time to Cath between 1 and 4 hours
Randomize 1:1: N=3000
Double Blind Double Dummy
*Only 5U if ≥75yr
Placebo Placebo
Placebo Abciximab
Reteplase (5U+5U)* Abciximab
Transfer To Cath Lab
ASA, unfractionated heparin 40U/kg (max 3000U)
or enoxaparin (0.5 mg/kg IV mg/kg SC) – substudy only
Abciximab
Placebo
Placebo
Primary PCI with Abciximab Infusion (12 h)
Follow up through 90 days and 1 year 1

2. FINESSE Results: Primary and Secondary Endpoints
Primary PCI (%)
Abciximab- facilitated (%)
Combination (abciximab/ reteplase)- facilitated (%)
Combination- facilitated vs primary PCI (P)
Combination- facilitated vs abciximab- facilitated (P)
Primary end point *
10.7
10.5
9.8 NS
All-cause mortality
4.5
5.5
5.2
Complications of MI
8.9
7.5
7.4
CHF requiring hospital/ ED visit
2.2
2.9
1.9
Death
* All cause mortality; rehospitalization or ED treatment for CHF; resuscitated ventricular fibrillation occurring > 48 hours after randomization; cardiogenic shock ED=emergency department
Ellis S. European Society of Cardiology Congress 2007; September 3, 2007; Vienna, Austria

3. FINESSE Results: Safety (Bleeding) Endpoints
Primary PCI (%)
Abciximab-facilitated (%)
Combination (abciximab/ reteplase)- facilitated (%)
Combination- facilitated vs primary PCI (P)
Combination- facilitated vs abciximab- facilitated (P)
TIMI major bleeding
2.6
4.1
4.8
0.025 NS
TIMI minor bleeding
4.3
6.0
9.7
<0.001
0.006
TIMI major or minor bleeding
6.9
10.1
14.5
0.008
Ellis S. European Society of Cardiology Congress 2007; September 3, 2007; Vienna, Austria

4. TIMI Flow in IRA Pre-PCI % Subjects with TIMI 2/3 (Patency) Pre-PCI
61 %
Percentage
25 %
TIMI 2
TIMI 3
25 %
26 %
11 %
36 %
12 %
15 %
13 %
Primary PCI (in lab Abciximab) (n=790)
Abciximab Facilitated PCI (n=809)
Reteplase/Abciximab Facilitated PCI (n=815)
Ave Time from First Abciximab Bolus min min to Angiogram in Facilitated Groups:
Modified ITT Population with Index PCI: ITT, PCI and any dose of study drug (active or placebo); Investigator assessment